Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03805503
Other study ID # EC/2014/1264
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date September 16, 2015
Est. completion date December 4, 2018

Study information

Verified date January 2019
Source University Hospital, Ghent
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to determine the minimum effective dose for intrathecal chloroprocaine in inguinal herniorrhaphy in outpatients using a Combined Spinal Epidural (CSE) anesthesia.


Description:

A standard CSE procedure will be conducted in which the patient is placed in an upright sitting position on the side of the operation table and a epidural Tuohy needle 18G will be inserted into L3-L4 interspace via a loss-of-resistance technique. The dura will be punctured using a 27-gauge pencil-point spinal needle and a certain dose of chloroprocaine 1% will be given. After the spinal needle is withdrawn, an epidural catheter will be placed and the epidural needle will be withdrawn. After fixation of catheter the patient will be placed in a supine position.

The first spinal dose of chloroprocaine 1% to start with is 50mg. This dose has been successfully used for spinal anesthesia in hernia repair outpatients to reach an adequate analgesia. Each time there will be added 2,5 microgram of sufentanil for prolongation of the analgesia. The testing interval is 2 mg.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date December 4, 2018
Est. primary completion date September 7, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Outpatients for unilateral inguinal hernia repair

- ASA I - II - III

Exclusion Criteria:

- hypersensitivity to amino-ester local anesthetics, para-aminobenzoic acid or sufentanil

- contraindications to spinal or epidural anesthesia

- bilateral inguinal herniorrhaphy

- extremes of height and weight (BMI 20 or 35 kg/m2, height 150 cm or 185 cm)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Chloroprocaine 1% Injectable Solution
standard CSE procedure in outpatients for inguinal hernia. The first spinal dose of chloroprocaine 1% to start with is 50mg. This dose has been successfully used for spinal anesthesia in hernia repair outpatients to reach an adequate analgesia. 2,5 microgram of sufentanil will be added for prolongation of the analgesia. The testing interval is 2 mg. Efficacy of the analgesia will be evaluated: Successful : sensory block at or above T6 dermatome bilateral at the beginning of surgery without additional analgesia during surgery. Unsuccessful: sensory block under T6 dermatome bilateral and/or VAPS is more than 10 mm at the beginning of surgery what necessitates additional epidurals analgesia. Patients who indicate an ineffective result will receive a rescue treatment by the administration of 5 ml chloroprocaine 3% epidural every 5 minutes with maximum of 30ml. When CSE fails, general anesthesia will be performed.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Ghent

Outcome

Type Measure Description Time frame Safety issue
Primary The dose of chloroprocaine 1% needed for the individual patient for a sensory anesthesia block at or above the T6 dermatome MLAD of chloroprocaine 1% with 2,5 mcg of sufentanil needed for the individual patient required for a sensory anesthesia at or above the T6 dermatome at the beginning of surgery with no additional epidural anesthesia required during surgery start of surgery
Secondary Peak block height highest sensible block during surgery
Secondary Time for regression of two segments Time for regression of two segments during surgery
Secondary Ambulation time motor recovery From starting hour of spinal anesthesia to hour of first ambulation after the end of surgery measured up to 6 hours after surgery
Secondary Time to micturition Time to micturition From starting hour of spinal anesthesia to hour of first micturition after the end of surgery measured up to 6 hours after surgery
Secondary Incidence of side effects (perioperative hypotension, respiratory depression, neurologic deficits) Incidence of side effects (perioperative hypotension, respiratory depression, neurologic deficits) perioperative
Secondary Time to discharge Time to discharge From starting hour of spinal anesthesia to hour of discharge from hospital measured up to 6 hours after surgery
Secondary Patient satisfaction with anesthesia method: questionnaire Patient satisfaction with simple questionnair (highly satisfied, satisfied, unsatisfied) postoperatively,at moment of hospital discharge measured up to 6 hours after surgery
See also
  Status Clinical Trial Phase
Completed NCT02565303 - Minimum Effective Dose of Ropivacaine for Spinal Anesthesia for Cesarean Delivery N/A
Recruiting NCT03248817 - Phenylephrine Infusion in Cesarean Delivery Phase 4
Completed NCT02840006 - Spinal Anesthesia Associated With General Anesthesia in Coronary Artery Bypass Phase 4
Completed NCT01624844 - Predictive Value of Ultrasound Measurement of the Dural Sac Volume on the Sensory Level in Spinal Anesthesia N/A
Recruiting NCT00974961 - Levobupivacaine on Heart Rate Variability (HRV) in Spinal Anesthesia Phase 4
Recruiting NCT00492453 - Spinal Versus General Anesthesia for Laparoscopic Cholecystectomy N/A
Completed NCT05549011 - PENG vs SIFI Block for Positioning Pain During Spinal Anesthesia
Completed NCT03775655 - Low Dose Hyperbaric Bupivacaine and Dexmedetomidine as an Adjuvant, Caesarean Section Phase 2/Phase 3
Completed NCT03199170 - Effect of Bilateral Quadratus Lumborum Block for Pain Relief in Patients With Cesarean Section N/A
Completed NCT03302039 - Three Protocols for Phenylephrine Administration in Cesarean Delivery Phase 4
Not yet recruiting NCT05063292 - Effect of Prewarming On Skin Temperature Changes N/A
Not yet recruiting NCT05583214 - Evaluating the Effectiveness of Ondansetron Versus Dexamethasone Versus Placebo for the Control of Intraoperative Nausea and Vomiting in Patients Undergoing Lower-segment Caesarean Section Under Spinal Anesthesia Phase 4
Recruiting NCT02937792 - Large Volume Bupivacaine 0.5% Versus Small Volume in Elective Caesarean Section N/A
Recruiting NCT01415284 - ED50 Determination of Hydroxyethylstarch for Treatment of Hypotension During Cesarean Section Under Spinal Anesthesia Phase 4
Completed NCT00537472 - Low Dose Spinal Bupivacaine for Total Knee Replacement and Recovery Room Wait Time N/A
Completed NCT05548985 - Midodrine for Prophylaxis Against Post Spinal Hypotension in Elderly Population N/A
Completed NCT03322098 - Effect of Atropine or Glycopyrrolate on the Prevention of Bradycardia During Sedation Using Dexmedetomidine in Geriatric Patients Undergoing Total Knee Replacement Under Spinal Anesthesia N/A
Recruiting NCT04598061 - IV Dexmedetomidine as Spinal Anesthesia Adjuvant in Infants
Completed NCT04083768 - Effect of Different Left Lateral Table Tilt for Elective Cesarean Delivery Under Spinal Anesthesia N/A
Completed NCT03702400 - Norepinephrine or Phenylephrine in Bolus for Hypotension in Cesarean Delivery Phase 2